Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc reaffirms FY 2014 guidance


Friday, 31 Jan 2014 06:30am EST 

ImmunoGen Inc:Sees fiscal 2014 revenues to be between $71 million and $75 million, unchanged from previous guidance.Sees fiscal 2014 net loss to be between $67 million and $71 million, unchanged from previous guidance.Fiscal 2014 revenue of $72 million - Thomson Reuters I/B/E/S. 

Company Quote

7.6
-0.19 -2.44%
27 Feb 2015